Venomyx Therapeutics

Venomyx Q4 2019 Investor Update

follower @ Venomyx Therapeutics

Published on Nov 21, 2019

Dear Venomyx Investors,

It is our pleasure to provide an end-of-year update to everyone who has supported our mission! has been 3 months since the close of our campaign and we have been hard at work both in and outside the lab. Our two main areas of focus are:

1) Continued research & development of Vipax to prepare for IND submission to FDA for clinical trials. We have just obtained venom samples of new species of snake for efficacy testing!

2) Fundraising for next round which will enable some very important milestones for us. We are currently in technical due diligence with a potential lead VC investor for our $3M round. We are also applying for grants to further or antivenom research as well as our bacterial antitoxin research to diversify our portfolio.

It is a very exciting time for us and we anticipate great results for 2020 with our primary objective of submitting our IND package. Thank you all again for your interest in our endeavors and support in getting our solution to market. Happy holidays and please tuned for our next update in March 2020!

Kind regards, 

Dan Dempsey